Stanford researchers identified a molecule called BRP that targets the hypothalamus to suppress appetite. Unlike semaglutide, which acts on gut and pancreas receptors, this compound focuses on a specific brain region to reduce hunger and fat loss.
The AI-driven approach bypassed the guesswork of traditional mass spectrometry by analyzing gene sequences for specific enzyme cuts. It remains an early stage animal study, so human trials are still needed to confirm whether this theoretical precision eliminates common side effects like nausea or muscle loss.
more: https://www.sciencedaily.com/releases/2026/11/261104004909.htm
my other side: ivo.blogspot.com
Leave a Reply